Background: Hepatocellular carcinoma (HCC) incidence and mortality are increasing in the United
A c c e p t e d M a n u s c r i p t 5 NYSCR routinely links cancer cases with state death certificates and the National Death Index to obtain vital status and related death information. Deaths through 2012 were included in this study. Underlying cause of death was recorded using ICD-10 codes. Cause of death was grouped into seven categories for analysis: HCC, other liver disease, other cancer, cardiovascular disease, HIV/AIDS-associated, substance abuse-related, and all other causes (see supplementary table 1 
for ICD-10 categorization).

Viral hepatitis data:
The study used HBV and HCV cases reported to DOHMH from 1999-2012. Viral hepatitis reporting improved substantially starting in 1999; to include individuals first reported to DOHMH before 1999, they needed to have at least one additional report received in 1999 or later. All
cases met the Centers for Disease Control and Prevention/Council of State and Territorial
Epidemiologists' case definition for confirmed or probable chronic HBV infection, or for past or present HCV infection [15, 16] .
Data matching:
The match of persons with HCC to viral hepatitis cases was conducted using Link Plus [17] , a program routinely used by NYSCR staff employing a probabilistic algorithm to match individuals.
Linkage variables included last name, first name, sex, birth date, and social security number. Link Plus matching was supplemented with manual review by NYSCR staff for borderline matches. The final deidentified dataset included all HCC cases diagnosed from 2001-2012 with HBV and HCV infection status. Ten cases where hepatitis infection was diagnosed after death were excluded.
Statistical Analysis: Descriptive analyses included examining the distribution of demographic and other characteristics of persons with HCC by viral hepatitis status (HBV mono-infection, HCV mono-infection, HBV/HCV coinfection, or neither infection). Comparisons of distributions between groups, using the neither infection group as the referent, were made using Wilcoxon 2-sample t tests for numeric variables and Chi-square tests for categorical variables, with a significance cut-off of p=0.01 to account for multiple comparisons.
A c c e p t e d M a n u s c r i p t among persons who died, comparing each viral hepatitis group with those with neither infection. Each cause of death was set as a binary outcome variable compared with all other causes. All models were adjusted for sex, age at HCC diagnosis, year of HCC diagnosis, cancer stage at diagnosis, race/ethnicity, and neighborhood poverty level. Models for death due to HCC or HIV/AIDS-related causes included significant interaction terms of disease stage by age at HCC diagnosis.
Kaplan-Meier survival analysis was used to calculate median survival time and survival probability for those with HCC, stratified by viral hepatitis status and cancer stage at diagnosis. Survival time was calculated from the date of HCC diagnosis to the date of death. Those alive as of December 31, 2012 were censored. The log-rank test with a Bonferroni correction to account for multiple comparisons was used to compare survival functions across groups.
A Cox proportional hazard model was used to quantify the risk of death in each viral hepatitis infection group compared with the neither infection group. The model adjusted for sex, age at HCC diagnosis, year of HCC diagnosis, cancer stage at diagnosis, race/ethnicity, and neighborhood poverty level. Due to an identified violation in the proportional hazards assumption for HCV infection, an interaction term between HCV and time was included in the model; hazard ratios for HCV were calculated separately at various time points. Survival analyses excluded HCC cases that were diagnosed by autopsy or death certificate only.
Statistical analysis was performed using SAS version 9.4 (SAS Institute; Cary, North Carolina). The NYC DOHMH and NYS DOH Institutional Review Boards approved the study. A significantly greater proportion of individuals with HBV mono-infection (52%) and HCV monoinfection (56%) lived in neighborhoods with high or very high poverty compared with those with neither infection (47%) ( Table 1) . When examining all residents with HCC within a given neighborhood poverty level, the proportion with HCV increased with increasing neighborhood poverty. Among persons with HCC living in low-poverty neighborhoods, 32% had HCV mono-infection. This proportion increased to 36% in medium-poverty neighborhoods and to 39% and 46% in high and very high poverty level neighborhoods, respectively (Cochran-Armitage test for trend, p<0.001). In contrast, approximately half (52%) of persons with HCC residing in low-poverty neighborhoods had neither infection reported.
Results
From
HBV mono-infected persons died at the youngest age (median: 57 years) and persons with neither infection died at the oldest age (median: 70 years) ( Table 2 ). The groups with viral hepatitis had significantly greater proportions of premature death (death before the age of 65 years [18] ) than the noninfected group. HCC was listed as the underlying cause of death for 66.1% of those who died.
Among persons who died, those with HBV mono-infection were more likely to die of HCC than those with neither infection (aOR 1.30, 95% CI 1.04-1.62); the odds of dying from HCC did not differ for those with HCV mono-infection or HBV/HCV coinfection ( Table 3) . Persons with HCV mono-infection had The risk of death for persons with HBV continued to be smaller than for those with neither infection, even after adjusting for numerous covariates (aHR=0.81, 95% CI: 0.73-0.89). At six months after HCC diagnosis, there was no significant difference in the risk of death for HCV mono-infected persons compared with those with neither infection (aHR=0.95, 95% CI: 0.90-1.02). However, the relative hazard of death increased over time and was significantly larger five years after HCC diagnosis (aHR=1.34, 95%
A c c e p t e d M a n u s c r i p t 9 CI 1.20-1.51). The risk of death for those with HBV/HCV coinfection was not significantly different from those with neither infection (see supplementary Table 3 ).
Discussion
Almost 60% of NYC residents with HCC had a viral hepatitis diagnosis; among those, 70% had HCV infection alone or with HBV, consistent with previous findings in the U.S. [6, 19] . Of note, 41% of HCC patients were not reported with either HBV or HCV infection, highlighting the importance of other HCC risk factors such as alcohol use and metabolic syndrome [20] . HCC patients with viral hepatitis were more likely to be diagnosed at a local stage and less likely to have an unknown stage, suggesting a higher degree of medical care. However, the proportion of diagnoses at a local stage was less than 50% for all groups, indicating improvements are needed in screening for HCC risk factors and early diagnosis of HCC.
Persons with HCC often lived in neighborhoods with high or very high poverty, particularly among those with HCV mono-infection. Many risk factors for HCC, including HCV and HBV infection, alcoholism, obesity, and metabolic syndrome are also associated with low socioeconomic status [21] . Individuals who reside in neighborhoods with a high poverty rate might also have limited access to healthcare, which could limit access to viral hepatitis screening and treatment and HCC screening [22, 23] .
The survival probability for those with HCC was low, with a median survival time of only 10.9 months, consistent with previously reported median survival times of 6-20 months [24] . Given that early diagnosis of HCC improves survival and increases the probability of cure [2] , these findings highlight the importance of screening and early treatment of HBV and HCV, as well as screening for HCC in persons with HBV or HCV infection or cirrhosis of any etiology [8, 25, 26] .
Unfortunately, HCC screening in the U.S. is not occurring according to recommendations. One study found that among non-cirrhotic patients with chronic HBV, only 6.7% were appropriately screened (one ultrasound every six months) and 33.7% did not receive HCC screening at all [27] . In another study of A c c e p t e d M a n u s c r i p t 10 those with HCV and cirrhosis, fewer than 50% of patients received HCC surveillance in the first year following cirrhosis diagnosis and only 12% received ongoing surveillance as recommended [28] . In a retrospective study of patients diagnosed with cirrhosis, fewer than 20% of those who developed HCC had received regular screening [29] . To improve its use, HCC screening according to expert recommendations must be facilitated and covered by all health insurances.
HBV mono-infected individuals in this study had better survival than all other groups, a finding that persisted regardless of HCC stage at diagnosis. Even after adjusting for age at diagnosis, stage at diagnosis, and other factors, the hazard of death was lower for those with HBV compared with those with HCV or with neither infection. It is possible that persons with non-HBV HCC risk factors are more likely to have co-occurring advanced liver disease and/or cirrhosis before developing HCC. Unlike with HBV, virtually all cases of HCV-related HCC occur only after cirrhosis develops [30] . Non-viral HCC risk factors, including alcoholic liver disease and NAFLD, also increase the risk for cirrhosis [31] . The presence of cirrhosis has been found to limit HCC treatment options, potentially reducing survival rates [32] . Our study found that decedents with HCV had greater odds of dying from other liver diseases, whereas decedents with HBV had greater odds of dying from HCC.
There are several limitations to this study. First, the number of viral hepatitis cases in the study population might be underestimated due to undiagnosed infections [33] , unreported infections, especially early in the study period before routine electronic laboratory reporting, under-matching of the viral hepatitis and cancer databases, and because some patients may have been diagnosed outside of NYC and thus not reported to DOHMH. Such misclassification would overestimate the number of non-infected persons, resulting in a dilution of the associations observed. Misclassification is also an issue when analyzing cause of death because death certificates can be unreliable [34] . This could affect the distributions of specific cause of death observed and emphasizes the need for improved death certificate accuracy.
Additionally, many individuals had an unknown tumor stage at diagnosis, which may be relevant if lacking cancer stage information is related to other factors associated with survival. It is unknown A c c e p t e d M a n u s c r i p t 11 whether patients had other HCC risk factors, were screened for HCC, or received viral hepatitis and/or HCC treatment. Also unknown was patient HIV status, which influences both on the occurrence of HCC and survival among those with HCV infection [35, 36] . Despite the above, this study provides a unique perspective on HCC in an urban setting with high viral hepatitis prevalence.
In this study, viral hepatitis was the largest contributor to HCC in NYC. Though important for those with HBV and cirrhosis from any cause, screening for HCC has its limitations. There is limited evidence for its use in persons with non-infectious risk factors (e.g. obesity, metabolic syndrome), a reduced ability of ultrasound to detect early stage HCC or detect HCC in obese patients, and logistical difficulties for providers in implementing screening procedures as recommended [37, 38] . Therefore, efforts targeted at preventing and treating HBV and HCV infections and preventing and managing obesity, excess alcohol use, and metabolic syndrome will be key to reducing the morbidity and mortality associated with HCC. In particular, highly effective and curative HCV treatments may reduce liver damage and subsequent HCC in HCV-infected persons, and treatment for all those with HCV should be a priority.
To further these efforts, health department activities to increase screening, linkage to care, and treatment for those with HCV, both through outreach and direct service programs, should continue to be supported with city, state, and federal funds. Additionally, advocacy efforts to pressure drug manufacturers to make HCV medications affordable and for health insurers to cover the medications without restriction must continue if access to treatment is to become widespread. While in some ways more difficult, prevention of obesity and metabolic syndrome must also remain a priority. Luckily, extensive attention has been given to the obesity epidemic in the U.S., and DOHMH has been aggressive in implementing system-wide policies to address root causes of obesity in the city. Such policies and other innovative programs will be vital in reducing the burden of HCC. 
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